Keywords: Lundbeck, Takeda, Lu AA21004, Ph III, US and European filings, Major depressive disorder

Lundbeck and Takeda to file for Lu AA21004 approval in USA and Europe on strong Ph III results

Article | 15 May 2012

Print This

Danish CNS drug specialist Lundbeck A/S (LUND: DC) yesterday announced positive top-line results from three recently completed Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in